Literature DB >> 14644135

The search for the CD8+ cell anti-HIV factor (CAF).

Jay A Levy1.   

Abstract

Efforts to control HIV infection have led to the development of several antiretroviral drugs that can limit virus replication, however, these therapies do not offer a long-term solution to the infection. We can learn a great deal from HIV-infected individuals who have lived for more than ten years and remain healthy without receiving antiviral drugs. These long-term survivors or long-term non-progressors have an immune system that can control HIV infection. A major component of this immune response is innate immunity, particularly the CD8(+) cell antiviral non-cytotoxic response (CNAR), mediated by a novel CD8(+) cell antiviral factor (CAF). The characteristics of CNAR and CAF will be described and progress made toward identifying CAF will be reviewed. These studies have uncovered several potentially important natural anti-HIV factors and their relationship to the originally described CAF is considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644135     DOI: 10.1016/j.it.2003.10.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  48 in total

Review 1.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages.

Authors:  Arevik Mosoian; Avelino Teixeira; Anthony A High; Robert E Christian; Donald F Hunt; Jeffrey Shabanowitz; Xinyan Liu; Mary Klotman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

4.  Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.

Authors:  Arevik Mosoian; Avelino Teixeira; Colin S Burns; Leif E Sander; G Luca Gusella; Cijiang He; J Magarian Blander; Paul Klotman; Mary E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 5.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.

Authors:  Myron S Cohen; Nick Hellmann; Jay A Levy; Kevin DeCock; Joep Lange
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture.

Authors:  José W Rodríguez; Nat O Pagan; María C Ocasio; Zilka Ríos; Luis A Cubano; Nawal M Boukli; Miguel Otero; Robert Hunter; Madhavan P Nair; Eddy Rios-Olivares
Journal:  Am J Infect Dis       Date:  2007

7.  Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons.

Authors:  Steven R Fauce; Otto O Yang; Rita B Effros
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

8.  Association of IL-12+ DC with High CD3+CD4-DR+ lymphocyte counts in long-term HIV-infected hemophilia patients with clinically stable disease.

Authors:  Volker Daniel; Cord Naujokat; Mahmoud Sadeghi; Rainer Zimmermann; Angela Huth-Kühne; Gerhard Opelz
Journal:  J Clin Immunol       Date:  2007-09-19       Impact factor: 8.317

9.  The CD8+ cell non-cytotoxic antiviral response affects RNA polymerase II-mediated human immunodeficiency virus transcription in infected CD4+ cells.

Authors:  Dalibor Blazek; Fernando Teque; Carl Mackewicz; Matija Peterlin; Jay A Levy
Journal:  J Gen Virol       Date:  2015-10-23       Impact factor: 3.891

10.  CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy.

Authors:  M Scott Killian; Jeremy Roop; Sharon Ng; Frederick M Hecht; Jay A Levy
Journal:  J Clin Immunol       Date:  2009-02-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.